“…We checked mean levels of FVII before and after administration of the 2 rFVIIa preparations to prove FVII: C level was comparably increased. 6,38 In the previous studies, the rate of reported adverse events was 1% to 10%, [50][51][52][53][54][55][56][57][58][59][60] and the most of adverse events had been headache, rashes, hypertension, and rarely thrombosis. We did not encounter any thrombosis in either treatment groups.…”